Payment overview · 2025
General Payments
$1,745.22
81 reported records · 19 companies
Healthcare provider profile · identity verified
Phillip Berges
Allopathic & Osteopathic Physicians|Internal Medicine · PORT JEFFERSON, NY · NPI 1932556636
Verified facts
What the public records show
CMS Open Payments records show Phillip Berges received $1,745.22 in general payments during 2025 across 81 reported records.
Amgen Inc. accounted for 17.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 33 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Entresto, Farxiga, Jardiance, Mounjaro, Synthroid, Ubrelvy.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 75 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Ubrelvy by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Mounjaro by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $307.81 | 17.6% | 15 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $250.82 | 14.4% | 13 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $176.28 | 10.1% | 7 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $170.73 | 9.8% | 10 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $122.94 | 7.0% | 5 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $106.83 | 6.1% | 4 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $105.00 | 6.0% | 5 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $96.94 | 5.5% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $89.44 | 5.1% | 4 | 2025 |
| Tactile Systems Technology Inc | Unresolved — no canonical attribution shown | $66.50 | 3.8% | 2 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $44.53 | 2.5% | 2 | 2025 |
| Amneal Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $42.49 | 2.4% | 2 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $40.88 | 2.3% | 2 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $28.48 | 1.6% | 1 | 2025 |
| SANOFI PASTEUR INC. | Unresolved — no canonical attribution shown | $27.66 | 1.6% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $18.64 | 1.1% | 1 | 2025 |
| IBSA Pharma Inc. | Unresolved — no canonical attribution shown | $17.78 | 1.0% | 1 | 2025 |
| Phadia US Inc. | Unresolved — no canonical attribution shown | $16.32 | 0.9% | 1 | 2025 |
| Regeneron Healthcare Solutions, Inc. | Unresolved — no canonical attribution shown | $15.15 | 0.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,745.22 | 81 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $278.22 | 13 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $221.36 | 10 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $149.75 | 8 | 2025 |
Source payment records
|
|||||
| SYNTHROID Normalized: synthroid |
Drug | ABBVIE INC. | $128.15 | 7 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $120.40 | 5 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $106.83 | 4 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $105.00 | 5 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $101.07 | 5 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $96.94 | 4 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $94.99 | 4 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $92.08 | 5 | 2025 |
Source payment records
|
|||||
| Flexitouch Plus Normalized: flexitouch plus |
Device | Tactile Systems Technology Inc | $66.50 | 2 | 2025 |
Source payment records
|
|||||
| Nimbl Normalized: nimbl |
Device | Tactile Systems Technology Inc | $66.50 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $65.40 | 3 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $44.53 | 2 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $44.53 | 2 | 2025 |
Source payment records
|
|||||
| UNITHROID Normalized: unithroid |
Drug | Amneal Pharmaceuticals LLC | $42.49 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $41.95 | 2 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $40.88 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $36.70 | 3 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $29.59 | 2 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $28.48 | 1 | 2025 |
Source payment records
|
|||||
| FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE Normalized: flublok quadrivalent northern hemisphere |
Biological | SANOFI PASTEUR INC. | $27.66 | 1 | 2025 |
Source payment records
|
|||||
| FLUZONE HIGH-DOSE Normalized: fluzone high dose |
Biological | SANOFI PASTEUR INC. | $27.66 | 1 | 2025 |
Source payment records
|
|||||
| ENTRESTO Normalized: entresto |
Drug | Novartis Pharmaceuticals Corporation | $26.58 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $21.60 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $18.64 | 1 | 2025 |
Source payment records
|
|||||
| Flector Normalized: flector |
Drug | IBSA Pharma Inc. | $17.78 | 1 | 2025 |
Source payment records
|
|||||
| Licart Normalized: licart |
Drug | IBSA Pharma Inc. | $17.78 | 1 | 2025 |
Source payment records
|
|||||
| Tirosint Normalized: tirosint |
Drug | IBSA Pharma Inc. | $17.78 | 1 | 2025 |
Source payment records
|
|||||
| ImmunoCAP Normalized: immunocap |
Device | Phadia US Inc. | $16.32 | 1 | 2025 |
Source payment records
|
|||||
| DUPIXENT Normalized: dupixent |
Biological | Regeneron Healthcare Solutions, Inc. | $15.15 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $10.24 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ENTRESTO entresto |
2025 | Entresto | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 38 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 46 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 45 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| SYNTHROID synthroid |
2025 | Synthroid | 2024 | 75 | exact normalized | Medicare Part D |
| UBRELVY ubrelvy |
2025 | Ubrelvy | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
75 | 29 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
38 | 12 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
46 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
46 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
45 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
51 | 13 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 605 | 136 |
| Atorvastatin Calcium | Atorvastatin Calcium | 573 | 148 |
| Amlodipine Besylate | Amlodipine Besylate | 466 | 151 |
| Metoprolol Succinate | Metoprolol Succinate | 343 | 92 |
| Losartan Potassium | Losartan Potassium | 270 | 66 |
| Pantoprazole Sodium | Pantoprazole Sodium | 265 | 70 |
| Alprazolam | Alprazolam | 264 | 83 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 236 | 87 |
| Omeprazole | Omeprazole | 231 | 57 |
| Famotidine | Famotidine | 197 | 43 |
| Simvastatin | Simvastatin | 194 | 35 |
| Potassium Chloride | Potassium Chloride | 183 | 54 |
| Lisinopril | Lisinopril | 149 | 39 |
| Eliquis | Apixaban | 148 | 38 |
| Gabapentin | Gabapentin | 130 | 43 |
| Metformin Hcl | Metformin Hcl | 127 | 42 |
| Fluticasone Propionate | Fluticasone Propionate | 120 | 40 |
| Escitalopram Oxalate | Escitalopram Oxalate | 118 | 36 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 118 | 37 |
| Furosemide | Furosemide | 115 | 47 |
| Ezetimibe | Ezetimibe | 107 | 39 |
| Methylprednisolone | Methylprednisolone | 102 | 70 |
| Tamsulosin Hcl | Tamsulosin Hcl | 102 | 32 |
| Montelukast Sodium | Montelukast Sodium | 101 | 24 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 100 | 44 |
| Hydrochlorothiazide | Hydrochlorothiazide | 95 | 30 |
| Azithromycin | Azithromycin | 90 | 53 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 88 | 24 |
| Diclofenac Sodium | Diclofenac Sodium | 83 | 26 |
| Sertraline Hcl | Sertraline Hcl | 82 | 29 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 80 | 63 |
| Zolpidem Tartrate | Zolpidem Tartrate | 78 | 20 |
| Atenolol | Atenolol | 76 | 27 |
| Clopidogrel | Clopidogrel Bisulfate | 76 | 27 |
| Synthroid | Levothyroxine Sodium | 75 | 29 |
| Repatha Sureclick | Evolocumab | 74 | 15 |
| Metoprolol Tartrate | Metoprolol Tartrate | 69 | 25 |
| Ibuprofen | Ibuprofen | 68 | 23 |
| Nebivolol Hcl | Nebivolol Hcl | 67 | 17 |
| Prednisone | Prednisone | 66 | 29 |
| Pravastatin Sodium | Pravastatin Sodium | 63 | 21 |
| Metformin Hcl Er | Metformin Hcl | 61 | 26 |
| Tizanidine Hcl | Tizanidine Hcl | 60 | 25 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 56 | 16 |
| Alendronate Sodium | Alendronate Sodium | 54 | suppressed |
| Irbesartan | Irbesartan | 53 | 18 |
| Ozempic | Semaglutide | 51 | 13 |
| Trazodone Hcl | Trazodone Hcl | 51 | 17 |
| Clonazepam | Clonazepam | 49 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 48 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 46 | 40 |
| Jardiance | Empagliflozin | 46 | 12 |
| Allopurinol | Allopurinol | 45 | 17 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 45 | 15 |
| Lorazepam | Lorazepam | 45 | 13 |
| Mounjaro | Tirzepatide | 45 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 43 | 17 |
| Pitavastatin Calcium | Pitavastatin Calcium | 43 | 16 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 42 | 27 |
| Doxycycline Hyclate | Doxycycline Hyclate | 42 | 31 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 42 | suppressed |
| Bupropion Xl | Bupropion Hcl | 41 | 15 |
| Generlac | Lactulose | 41 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 41 | 18 |
| Amoxicillin | Amoxicillin | 40 | 27 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 40 | 29 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 40 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 39 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 38 | 12 |
| Ondansetron Odt | Ondansetron | 38 | 13 |
| Celecoxib | Celecoxib | 37 | suppressed |
| Spironolactone | Spironolactone | 37 | 13 |
| Diazepam | Diazepam | 35 | 15 |
| Fenofibrate | Fenofibrate Nanocrystallized | 34 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 34 | suppressed |
| Baclofen | Baclofen | 33 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 33 | suppressed |
| Mupirocin | Mupirocin | 33 | 24 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 33 | suppressed |
| Nystatin | Nystatin | 31 | suppressed |
| Vascepa | Icosapent Ethyl | 31 | suppressed |
| Naproxen | Naproxen | 30 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 30 | 11 |
| Torsemide | Torsemide | 30 | 13 |
| Xarelto | Rivaroxaban | 30 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 29 | 12 |
| Methocarbamol | Methocarbamol | 29 | suppressed |
| Carvedilol | Carvedilol | 28 | 11 |
| Januvia | Sitagliptin Phosphate | 28 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 26 | suppressed |
| Lovastatin | Lovastatin | 26 | suppressed |
| Meloxicam | Meloxicam | 26 | suppressed |
| Nyamyc | Nystatin | 26 | suppressed |
| Clindamycin Phosphate | Clindamycin Phosphate | 25 | suppressed |
| Hydrocortisone | Hydrocortisone | 25 | suppressed |
| Valsartan | Valsartan | 25 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 24 | suppressed |
| Linzess | Linaclotide | 24 | suppressed |
| Livalo | Pitavastatin Calcium | 24 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 24 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 24 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Nitroglycerin | Nitroglycerin | 23 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 23 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 22 | suppressed |
| Finasteride | Finasteride | 22 | 11 |
| Nifedipine Er | Nifedipine | 22 | suppressed |
| Telmisartan | Telmisartan | 22 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 22 | suppressed |
| Entresto | Sacubitril/Valsartan | 21 | suppressed |
| Myrbetriq | Mirabegron | 21 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 20 | suppressed |
| Levetiracetam | Levetiracetam | 20 | suppressed |
| Lidocaine | Lidocaine | 20 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 20 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 20 | 11 |
| Edarbi | Azilsartan Medoxomil | 19 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 19 | suppressed |
| Praluent Pen | Alirocumab | 19 | suppressed |
| Fenofibric Acid | Fenofibric Acid (Choline) | 18 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 18 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 18 | suppressed |
| Aripiprazole | Aripiprazole | 17 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 17 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 17 | suppressed |
| Glimepiride | Glimepiride | 17 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 17 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 16 | suppressed |
| Epinephrine | Epinephrine | 16 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 16 | suppressed |
| Mirabegron Er | Mirabegron | 16 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 15 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 15 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Folic Acid | Folic Acid | 15 | suppressed |
| Ketoconazole | Ketoconazole | 15 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 15 | suppressed |
| Mirtazapine | Mirtazapine | 15 | suppressed |
| Tobramycin | Tobramycin | 15 | suppressed |
| Atomoxetine Hcl | Atomoxetine Hcl | 14 | suppressed |
| Klor-Con M10 | Potassium Chloride | 14 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 14 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 14 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 14 | suppressed |
| Verapamil Er | Verapamil Hcl | 14 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 13 | suppressed |
| Carisoprodol | Carisoprodol | 13 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 13 | 11 |
| Cephalexin | Cephalexin | 13 | suppressed |
| Cinacalcet Hcl | Cinacalcet Hcl | 13 | suppressed |
| Fluconazole | Fluconazole | 13 | suppressed |
| Glipizide Er | Glipizide | 13 | suppressed |
| Levofloxacin | Levofloxacin | 13 | 11 |
| Memantine Hcl | Memantine Hcl | 13 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 13 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 13 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 13 | suppressed |
| Fenofibrate | Fenofibrate | 12 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 12 | suppressed |
| Klor-Con M20 | Potassium Chloride | 12 | suppressed |
| Lubiprostone | Lubiprostone | 12 | suppressed |
| Rexulti | Brexpiprazole | 12 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 12 | suppressed |
| Rybelsus | Semaglutide | 12 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 12 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 11 | suppressed |
| Butalbital-Aspirin-Caffeine | Butalbital/Aspirin/Caffeine | 11 | suppressed |
| Eszopiclone | Eszopiclone | 11 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 11 | suppressed |
| Nadolol | Nadolol | 11 | suppressed |
| Pregabalin | Pregabalin | 11 | suppressed |
| Ramipril | Ramipril | 11 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 11 | suppressed |
| Ubrelvy | Ubrogepant | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,745.22 · 81 records | Amgen Inc. | AIRSUPRA, BREZTRI, CAPLYTA, CAPVAXIVE, Cologuard Collection Kit, DUPIXENT, ENTRESTO, EVENITY, FARXIGA, FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE, FLUZONE HIGH-DOSE, Flector, Flexitouch Plus, GARDASIL 9, GEMTESA, ImmunoCAP, JARDIANCE, JOURNAVX, LEQVIO, Licart, MOUNJARO, NEXLETOL, Nimbl, OTEZLA, PROLIA, QULIPTA, REPATHA, SYNTHROID, Tirosint, UBRELVY, UNITHROID, VRAYLAR, ZEPBOUND | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Entresto play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error